دورية أكاديمية

Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)

التفاصيل البيبلوغرافية
العنوان: Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)
المؤلفون: Sakurai Kouichi, Nagahara Akihito, Inoue Kazuhiko, Akiyama Junichi, Mabe Katsuhiro, Suzuki Junichi, Habu Yasuki, Araki Akihiro, Suzuki Tsuyoshi, Satoh Katsuaki, Nagami Haruhiko, Harada Ryosaku, Tano Nobuo, Kusaka Masayasu, Fujioka Yasuhiko, Fujimura Toshikatsu, Shigeto Nobuyuki, Oumi Tsuneyo, Miwa Jun, Miwa Hiroto, Fujimoto Kazuma, Kinoshita Yoshikazu, Haruma Ken
المصدر: BMC Gastroenterology, Vol 12, Iss 1, p 42 (2012)
بيانات النشر: BMC, 2012.
سنة النشر: 2012
المجموعة: LCC:Diseases of the digestive system. Gastroenterology
مصطلحات موضوعية: Omeprazole, Famotidine, Mosapride, Teprenone, Uninvestigated upper gastrointestinal symptoms, Diseases of the digestive system. Gastroenterology, RC799-869
الوصف: Abstract Background In Japan, treatment guidelines are lacking for patients with upper gastrointestinal symptoms. We aimed to compare the efficacy of different drugs for the treatment of uninvestigated upper gastrointestinal symptoms. Methods This was a randomized, open-label, parallel-group multicenter study. Helicobacter pylori-negative, endoscopically uninvestigated patients ≥ 20 years of age with upper gastrointestinal symptoms of at least moderate severity (Global Overall Symptom score [GOS] ≥ 4 on a 7-point Likert scale) were randomized to treatment with omeprazole (10 mg once daily), famotidine (10 mg twice daily), mosapride (5 mg three times daily) or teprenone (50 mg three times daily). The primary endpoint was sufficient relief of upper gastrointestinal symptoms after 4 weeks of treatment (GOS ≤ 2). UMIN clinical trial registration number: UMIN000005399. Results Of 471 randomized patients, 454 were included in the full analysis set. After 4 weeks of treatment, sufficient symptom relief was achieved by 66.9% of patients in the omeprazole group, compared with 41.0%, 36.3% and 32.3% in the famotidine, mosapride and teprenone groups, respectively (all, p Conclusions The favorable efficacy and safety profiles of omeprazole in relieving uninvestigated upper gastrointestinal symptoms support its use as first-line treatment in this patient group in Japan. Patients who show no improvement in symptoms despite PPI use, and those with alarm symptoms (such as vomiting, GI bleeding or acute weight loss) should receive further investigation, including prompt referral for endoscopy. Trial registration UMIN000005399.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1471-230X
Relation: http://www.biomedcentral.com/1471-230X/12/42; https://doaj.org/toc/1471-230X
DOI: 10.1186/1471-230X-12-42
URL الوصول: https://doaj.org/article/c190ffbf21ab40fd9c3fbc3e290d4fe0
رقم الأكسشن: edsdoj.190ffbf21ab40fd9c3fbc3e290d4fe0
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:1471230X
DOI:10.1186/1471-230X-12-42